Head-to-head comparison of micafungin versus caspofungin in the treatment of invasive candidiasis

Abstract

Introduction: Invasive candidiasis is an important cause of morbidity and mortality among patients with health care–associated infection. The echinocandin class of antifungal agents has demonstrated consistent effi cacy and a favorable safety profi le in the treatment of candidemia and other forms of invasive candidiasis. The in vitro antifungal activity, pharmacokinetics, and toxicity profi les are slightly different for each echinocandin; however, the relevance of this fi nding is unclear. There are no clinical trials comparing the safety and effi cacy of different echinocandins in the treatment of invasive candidiasis.